Company intelligence / Profile preview
Orient Pharma Co., Ltd.
Taipei, Taipei City, Taiwanoppharma.com ↗
- Ownership
- Public · 4166
- Employees
- ~177
- Development stage
- Phase 2
01
Overview
Orient Pharma has received FDA approval for multiple products including the generic muscle relaxant Carisoprodol and the hypolipidemic generic drug Pitavastatin. The company has passed US FDA site inspection.
- Therapeutic areas
- CardiovascularNeurology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
ActavisSupernus Pharmaceuticals
04
Financials
- Market cap
- $163.2M
- Total revenue
- $42.7M
- Enterprise value
- $151.1M
Beyond the preview
Go deeper on Orient Pharma Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Orient Pharma Co., Ltd..